Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 mice
Hayley S. McLoughlin(University of Michigan), Henry L. Paulson(University of Michigan)
Cited by 156
Related Papers
Ubiquitination directly enhances activity of the deubiquitinating enzyme ataxin‐3
|The EMBO Journal|2009|170
Comparison of spinocerebellar ataxia type 3 mouse models identifies early gain-of-function, cell-autonomous transcriptional changes in oligodendrocytes
|Human Molecular Genetics|2017|55
Loss of the Ubiquitin-conjugating Enzyme UBE2W Results in Susceptibility to Early Postnatal Lethality and Defects in Skin, Immune, and Male Reproductive Systems
|Journal of Biological Chemistry|2015|28
ASOs are an effective treatment for disease-associated oligodendrocyte signatures in premanifest and symptomatic SCA3 mice
|Molecular Therapy|2024|19
Disease-associated oligodendrocyte signatures are spatiotemporally dysregulated in spinocerebellar ataxia type 3
|Frontiers in Neuroscience|2023|16